Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

PURPOSE: Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach....

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yong, Carrio, Ignasi, De Vincentis, Giuseppe, Fanti, Stefano, Ilhan, Harun, Mommsen, Caroline, Nitzsche, Egbert, Sundram, Francis, Vogel, Wouter, Oyen, Wim, Lewington, Val
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537325/
https://www.ncbi.nlm.nih.gov/pubmed/28631036
http://dx.doi.org/10.1007/s00259-017-3756-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537325/
https://www.ncbi.nlm.nih.gov/pubmed/28631036
http://dx.doi.org/10.1007/s00259-017-3756-7

Ejemplares similares